|
For more than five years, Auspex Pharmaceuticals has focused on expanding the applications of deuteration technology and
its IP portfolio.
We now have filed patents on several hundred deuterated versions of existing molecules that represent a broad range of therapeutic areas. We are now accelerating the development of multiple clinical candidates.
On May 6, we
announced:
- A $13.875M Series B financing
round led by Thomas, McNerney & Partners
with participation from co-investors CMEA Ventures and Costa Verde Capital
-
The addition of Ajit Gill as
president and chief executive officer
For full details,
please read the news release below.
Our vision is to be the
leading deuteration company with a developing
pipeline of best-in-class therapeutics that
improve on existing drugs across multiple
therapeutic areas. We are working on a brand
new website, which will launch in early
summer 2008.
Meanwhile, please read our
latest news release. |
|
|
Interested in
partnering with us or learning about a
career at Auspex?
Please contact us at the
email address below.
If you would like to be
notified when our new site goes live, please
give us your email address in the box below.
Thank you for your interest.
Auspex Pharmaceuticals
1261 Liberty Way, Suite
C
Vista,
CA
92081
760-599-1800
|
